Results 231 to 240 of about 140,556 (355)
Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics
Journal of the European Academy of Dermatology and Venereology, EarlyView.Forty‐three HS specialists from 22 European countries reported adherence to HS guidelines and use of antibiotics before biologics despite limited efficacy and rapid relapse (49% within 1–3 months). Seventy‐nine per cent supported short‐term biologics for severe Hurley I disease.Georgios Nikolakis, Erkan Alpsoy, Monika Arenbergerova, Falk G. Bechara, Farida Benhadou, Joana Cabete, Raffaele Dante Caposiena Caro, Giovanni Damiani, Maia Delage Toriel, Veronique Del Marmol, Valentina Dini, Evangelos J. Giamarellos‐Bourboulis, Katalin Glasenhardt, Philippe Guillem, Ariela Hafner, Evgeniya Hristakieva, John R. Ingram, Vaiva Jarienè, Gregor B. E. Jemec, Niamh Kearney, Brian Kirby, Natalia Kirsten, Piotr K. Krajewski, Vesta Kucinskiene, Aikaterini I. Liakou, Flavia Manzo Margiotta, Angelo V. Marzano, Antonio Martorell, Lukasz Matusiak, Dillon Mintoff, Alejandro Molina Leyva, Francesca Prignano, Tadas Raudonis, Hans Christian Ring, Marco Romanelli, Samed Şahin, Ditte M. L. Saunte, Linnea Thorlacius, Thrasyvoulos Tzellos, Hessel H. Van Der Zee, Kelsey Van Straalen, Christos C. Zouboulis +41 morewiley +1 more sourceHair follicle stem cell fate supports distinct clinical endotypes in hidradenitis suppurativa
Journal of the European Academy of Dermatology and Venereology, EarlyView.Hair follicles (HFs) were extracted from skin biopsies. From these, original sequencing data were obtained and integrated with two independent studies to build a HF single‐cell transcriptomic atlas. It enabled delineating the fate of HF stem cells.Audrey Onfroy, Francette Jean‐Louis, Philippe Le Corvoisier, Fanny Coulpier, Kévin Muret, Eric Bonnet, Raphaele Arrouasse, Caroline Boucle, Salwa Abid, Emilie Sbidian, Christina Bergqvist, Pierre Wolkenstein, Véronique Godot, Jean‐François Deleuze, Yves Lévy, Piotr Topilko, Etienne Audureau, Sophie Hue +17 morewiley +1 more sourceEfficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial
Journal of the European Academy of Dermatology and Venereology, EarlyView.This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background
The efficacy and safety of brodalumab in Masamoto Murakami, Yukari Okubo, Satomi Kobayashi, Natsuko Kikuta, Yoshiumi Ouchi, Kenta Shishido, Tadashi Terui +6 morewiley +1 more sourceSafety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years
Journal of the European Academy of Dermatology and Venereology, EarlyView.The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background
Atopic dermatitis (Christopher G. Bunick, Alan D. Irvine, Jonathan I. Silverberg, Emma Guttman‐Yassky, Mona Shahriari, Xinghua Gao, Stephan Weidinger, Norito Katoh, Namita Vigna, Deanne M. Dilley, Elvira D'Andrea, Henrique D. Teixeira, Andrew M. Platt, Gweneth F. Levy +13 morewiley +1 more sourceGlobal consensus on the management of melanin hyperpigmentation disorders
Journal of the European Academy of Dermatology and Venereology, EarlyView.A global Delphi consensus of 10 dermatology experts established evidence‐based recommendations for melanin hyperpigmentation disorders, providing unified classification, photoprotection guidance and treatment algorithms. This framework harmonizes terminology and supports individualized management across diverse skin types and health systems.Thierry Passeron, Seemal R. Desai, Marwa Abdallah, Firas Al‐Niaimi, Ncoza Dlova, Pearl E. Grimes, Jorge Ocampo‐Candiani, Rashmi Sarkar, Leihong Flora Xiang, Helio Amante Miot +9 morewiley +1 more sourceDelphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa
Journal of the European Academy of Dermatology and Venereology, EarlyView.This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.Georgios Nikolakis, Erkan Alpsoy, Florian Anzengruber, Matthias Augustin, Falk G. Bechara, Pierre‐André Becherel, Farida Benhadou, Vincenzo Bettoli, Joana Cabete, Raffaele Dante Caposiena Caro, Antonella Di Cesare, Giovanni Damiani, Valentina Dini, Evangelos J. Giamarellos‐Bourboulis, Krisztián Gáspár, Katalin Glasenhardt, Philippe Guillem, Ariela Hafner, Barbara Horvath, John R. Ingram, Vaiva Jarienè, Gregor B. E. Jemec, Alexander Katoulis, Natalia Kirsten, Georgios Kokolakis, Piotr K. Krajewski, Aikaterini I. Liakou, Flavia Manzo Margiotta, Angelo V. Marzano, Antonio Martorell, Lukasz Matusiak, Dillon Mintoff, Alejandro Molina Leyva, Andreas Pinter, Anna Pirogova, Maurizio Podda, Francesca Prignano, Jorge Romani, Marco Romanelli, Elia Rosi, Samed Sahin, Ditte M. L. Saunte, Sylke Schneider‐Burrus, Mariano Suppa, Jacek Szepietowski, Andrea Szegedi, Simon Francis Thomsen, Thrasyvoulos Tzellos, Anastasia Trigoni, Hessel H. Van Der Zee, Kelsey Van Straalen, Skaidra Valiukevičiene, Eva Vilarrasa, Esther von Stebut, Christos C. Zouboulis +54 morewiley +1 more source